In this prospective study, we review the clinical studies showing the prognostic relevance of TP53 mutations in MCL, their impact on therapeutic decision-making [29], and the technologies used in most diagnostic and research laboratories. The gene discussed is TP53; the disease is mantle cell lymphoma.